Hospital

Despite suggestions to the contrary in previously conducted small clinical trials, montelukast did not provide benefit in patients with COVID-19 symptoms.

Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

Pharmacists are positioned to combat the opioid crisis through educating the public and advocating for policy changes to enable harm reduction strategies.

In April 2024, the FDA approved ustekinumab-aekn as a subcutaneous injection for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

There are gonadotoxic risks of chemotherapy, radiation, and surgery that are important to discuss with patients.

Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.

Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.

The implementation of accountable care organizations (ACOs) also worsened disparities in any emergency department or hospital use for Medicaid-insured children with asthma.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

The connection of F proteins could help destabilize the virus prior to infection of the next host.

The results emphasize the need for pharmacists and health care providers to further educate patients about receiving recommended immunizations.

The additions include Dextrose 70% intravenous (IV) solution, Lactated Ringers IV Solution, and Peritoneal Dialysis Solution, which were affected by Hurricane Helene.

Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.

Research funding that aims to understand impacts of systemic racism on pediatric asthma should include plans to undo policies that maintain inequities created by systemic racism.

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

The gold standard of testing for food allergies is an oral food challenge test where patients consume the allergen, such as peanut extract, under supervision.

This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.

The guidelines emphasize the importance of vaccination, risk assessment, and preparedness for immunocompromised patients who are traveling post-transplant.

The KEYNOTE-756 and CheckMate 7FL trials show this combination improves pathological complete response rates in this patient population.

Pharmacogenomic testing can help identify patients' genetic profiles, revealing why certain drugs may be less effective or cause adverse effects.

Cardiovascular diseases have a significant impact on brain health and function.

The increase was observed across multiple subgroups, including those with overweight or obesity and hospitalized patients.

The drug's safety profile included significant rates of nausea, vomiting, and hematologic toxicities like neutropenia and thrombocytopenia. Although promising, brigimadlin requires careful management of adverse effects, including antiemetic and hematologic support.

Advanced cell therapies are now saving the lives of people whose blood cancer would previously have been incurable. While the UK was quick to recognize the potential of these innovative therapies, patient access to these therapies may change without continued investment in the UK's cell therapy infrastructure.

Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.

Although respondents identified some exciting areas of growth, challenges remain, including the complex insurance system and ensuring patient medication adherence.